Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. Read the full analysis here.

Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsAlexander Cumbo - ...

Darell Hernaiz's homer was the second walk-off of the day, after Ozzie Albies made history with the first walk-off homer in WBC history.

When you’re running a side hustle, you can get away with inconsistent branding and a personal email address because your ...

Another new name tops this week's rankings after INDYCAR's inaugural Grand Prix of Arlington.

Historically speaking, if a running back is going to be a factor at Nebraska, they tend to flash in year one. Can Jamal Rule join that group, and if he does, what does it mean?

RentRedi reports landlords should keep meticulous records, separate business and personal finances, utilize technology, and ...

Fifty-four members from MLB Pipeline’s Top 100 are scheduled to play in the third edition of Spring Breakout, including ...

There's a solid group available, though teams may have to turn to some aging veterans ...

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex ...

The Wild's pool looks a lot different today than it has in recent years after high-profile graduations and trades.